Scarica l'app Stockscreener
58.01
1.60%
0.915
Dopo l'orario di chiusura:
58.01
0.005
+0.01%
Precedente Chiudi:
$57.09
Aprire:
$56.76
Volume 24 ore:
374.03K
Relative Volume:
1.09
Capitalizzazione di mercato:
$1.18B
Reddito:
$1.77M
Utile/perdita netta:
$-123.74M
Rapporto P/E:
-6.3255
EPS:
-9.17
Flusso di cassa netto:
$-95.21M
1 W Prestazione:
+5.58%
1M Prestazione:
+31.95%
6M Prestazione:
-24.78%
1 anno Prestazione:
+1.57%
Intervallo 1D:
$55.96
$58.44
Intervallo di 1 settimana:
$53.72
$59.10
Portata 52W:
$26.70
$91.83
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Nome
Praxis Precision Medicines Inc
Settore
Industria
Telefono
617-300-8460
Indirizzo
99 HIGH STREET, 30TH FLOOR, BOSTON
Confronta PRAX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
58.01 | 1.16B | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-02 | Ripresa | Oppenheimer | Outperform |
| 2025-05-07 | Iniziato | Chardan Capital Markets | Buy |
| 2025-03-03 | Reiterato | H.C. Wainwright | Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-08-05 | Iniziato | Oppenheimer | Outperform |
| 2024-06-24 | Iniziato | Needham | Buy |
| 2024-06-18 | Iniziato | Guggenheim | Buy |
| 2024-05-01 | Iniziato | Robert W. Baird | Outperform |
| 2023-09-19 | Iniziato | Truist | Buy |
| 2022-06-06 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-12-16 | Iniziato | H.C. Wainwright | Buy |
| 2021-08-26 | Iniziato | BofA Securities | Buy |
| 2021-04-26 | Iniziato | William Blair | Outperform |
| 2020-11-11 | Iniziato | Wedbush | Outperform |
| 2020-11-10 | Iniziato | Cowen | Outperform |
| 2020-11-10 | Iniziato | Evercore ISI | Outperform |
| 2020-11-10 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Praxis Precision Medicines Inc Borsa (PRAX) Ultime notizie
Is Praxis Precision Medicines Inc. a good long term investmentExceptional profit potential - PrintWeekIndia
Will Praxis Precision Medicines Inc. stock benefit from AI tech trendsTremendous return rates - jammulinksnews.com
What analysts say about Praxis Precision Medicines Inc. stock outlookSky-high return potential - jammulinksnews.com
Praxis Precision Medicines Inc. Stock Analysis and ForecastFree Risk Assessment Services - Autocar Professional
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
What analysts say about Praxis Precision Medicines Inc. stockBreakthrough capital growth - jammulinksnews.com
What drives Praxis Precision Medicines Inc. stock priceConsistent triple-digit returns - jammulinksnews.com
Major Depressive Disorder Clinical Trials, Companies, - openPR.com
What makes Praxis Precision Medicines Inc. stock price move sharplyFree Stock Selection - Newser
Does Praxis Precision Medicines Inc. stock pay reliable dividendsShort Squeeze Radar - Newser
Why Praxis Precision Medicines Inc. stock attracts strong analyst attentionGroup Only Stock Signals - Newser
Praxis Precision Medicines’ (PRAX) Buy Rating Reiterated at HC Wainwright - Defense World
(PRAX) Trading Report - news.stocktradersdaily.com
Here's Why We're Not Too Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Situation - 富途牛牛
Praxis Precision Medicines stock gets BTD for relutrigine, H.C. Wainwright maintains Buy - Investing.com Nigeria
Praxis Precision Medicines stock gets BTD for relutrigine, H.C. Wainwright maintains Buy By Investing.com - Investing.com South Africa
PRAX: HC Wainwright & Co. Reiterates Buy Rating with $105 Target - GuruFocus
Praxis Precision gets FDA breakthrough therapy status for Relutrigine - Seeking Alpha
FDA grants breakthrough therapy designation to Praxis’ relutrigine for pediatric epilepsy - Investing.com Canada
Q1 Earnings Forecast for PRAX Issued By HC Wainwright - Defense World
Praxis Precision Medicines and the Breakthrough Potential of Relutrigine in Rare Epilepsy Therapies: Strategic and Financial Implications of FDA Breakthrough Therapy Designation - AInvest
Praxis Says FDA Grants Breakthrough Therapy Designation To Relutrigine For Rare Pediatric Epilepsies - Nasdaq
FDA grants breakthrough therapy status to Praxis’s relutrigine By Investing.com - Investing.com Canada
FDA grants breakthrough therapy status to Praxis’s relutrigine - Investing.com Australia
Praxis Precision Medicines Gains FDA Breakthrough Designation - TipRanks
PRAX Gains FDA Breakthrough Designation for Pediatric Epilepsy D - GuruFocus
Praxis Precision Medicines Receives Breakthrough Therapy Designation for Relutrigine in Pediatric Developmental and Epileptic Encephalopathies - Quiver Quantitative
Praxis Precision Medicines Receives FDA Breakthrough - GlobeNewswire
Praxis's Rare Epilepsy Drug Achieves FDA Breakthrough Status: 90% Seizure Reduction in Trial Patients - Stock Titan
Praxis Precision Medicines Inc Azioni (PRAX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):